SMA
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
150%
Gene Therapy
150%
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Scholar RockMA - Cambridge
1 programApitegromabN/AMonoclonal Antibody1 trial
Active Trials
NCT06877689No Longer Available
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SandozOnasemnogene Abeparvovec-xioi
Clinical Trials (2)
Total enrollment: 33 patients across 2 trials
Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
Start: Aug 2018Est. completion: Sep 202033 patients
Phase 3Completed
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
N/ANo Longer Available
Related Jobs
Senior Medical Science Liaison
Shanghai, China (Field Based)
1w ago
Director of Finance, US Rare Disease
Cambridge, MA (Hybrid)
3w ago
$188K - $259K/yr
Associate Program Director- Rare Disease
Cambridge, MA (Hybrid)
4w ago
$162K - $223K/yr
Director, Product Communications, Rare Disease
Cambridge, MA (Hybrid)
4w ago
$192K - $264K/yr
Regional Market Access Manager (Location: Guangzhou)
Shanghai, China (Field Based)
1mo ago
Patient Journey Partner - Rare Diseases
Dubai
1mo ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
Monoclonal Antibody is the dominant modality (50% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.